Immix Biopharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ticker: IMMX) is a United States-based biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Los Angeles, California, and founded in 2012, the company fits the profile of a clinical-stage biotech: it has not yet built a broad commercial product franchise, but instead concentrates capital and scientific effort on the development of novel therapies for severe diseases with significant unmet medical need. The company’s core business is research and development in cell therapy, with a particular focus on relapsed/refractory AL amyloidosis and other immune-mediated diseases. Its lead asset is NXC-201, a CAR-T candidate being developed for complex hematologic and inflammatory indications. Immix Biopharma has emphasized clinical updates at major medical and scientific conferences, underscoring a development strategy centered on data generation, medical credibility, and eventual regulatory progression rather than near-term product sales. For investors, that means the company’s valuation is driven primarily by pipeline execution, clinical outcomes, and regulatory milestones, while operating cash burn and financing needs remain central considerations. From a historical perspective, Immix was built by a founding group combining medical, pharmacology, patent, and family-office experience, reflecting a mix of scientific ambition and capital-market discipline. Over time, the company expanded its structure through subsidiaries, including Nexcella, to support its therapeutic programs and clinical development efforts. This is common in biotech and can help isolate specific assets, partnerships, and development pathways. In competitive terms, Immix occupies a niche but potentially high-value segment within cell therapy, competing indirectly with larger biotechnology and pharmaceutical companies as well as smaller specialty biotechs pursuing rare-disease or immunology opportunities. Geographically, Immix is rooted in the United States, with corporate operations centered in California and a broader clinical and scientific footprint shaped by trial activity, publications, and conference participation. Recent highlights matter for the investment case: in 2026, the company announced U.S. FDA Breakthrough Therapy Designation for NXC-201, a meaningful regulatory signal that can accelerate development and heighten investor attention. The company has also remained active in capital raising and investor outreach, which is typical for a pre-commercial biotech advancing an expensive clinical program. Overall, Immix Biopharma is best viewed as a speculative clinical-stage biotech with a focused pipeline, a rare-disease orientation, and a high dependency on trial success and regulatory progress. For French, Belgian, and Swiss investors, IMMX offers exposure to a potentially differentiated cell-therapy story on the NASDAQ, but with the usual biotech risk profile: binary clinical outcomes, dilution risk, and long commercialization timelines.